Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2026 10:35 ET | Source: Applied Biologics

Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®

Applied Biologics' VA FSS contract shifts to Evergreen structure, enabling potential XWRAP® access for up to 20 years.
June 30, 2026 10:29 ET | Source: Applied Biologics

Applied Biologics Announces National Commercial Expansion to Support Continued Growth of XWRAP® and Future Biologic Product Pipeline

Applied Biologics expands its national commercial organization to support XWRAP® growth and future pipeline commercialization.
June 24, 2026 09:06 ET | Source: Applied Biologics

Applied Biologics Announces Completion of Translational Research Supporting the Biologic Performance of XWRAP®

Applied Biologics completes translational study showing XWRAP® exhibits favorable wound-healing biology vs. conventional placental tissue processing.
June 23, 2026 13:19 ET | Source: Applied Biologics

Applied Biologics Announces Submission of Abstract of Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of The Campx Trial to SAWC Fall 2026

Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.
June 17, 2026 11:38 ET | Source: Applied Biologics

Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®

Applied Biologics completes enrollment in the CAMPX RCT evaluating XWRAP® for chronic diabetic foot ulcers across 23 SerenaGroup sites.
June 15, 2026 10:03 ET | Source: Applied Biologics

Applied Biologics Reports Statistically Significant Improvement in Wound Closure Outcomes in Updated Analyses of the CAMPX Randomized Controlled Trial Evaluating XWRAP®

XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).
June 10, 2026 11:45 ET | Source: Applied Biologics

Applied Biologics Presents Interim CAMPX Clinical Trial Data at the Symposium on Advanced Wound Care (SAWC) Spring 2026

Applied Biologics presents interim CAMPX Trial data at SAWC Spring 2026, highlighting encouraging wound closure trends for XWRAP® in diabetic foot ulcers.